

TITOLO DI STUDIO

ESPERIENZA
PROFESSIONALE

(02/2011 - oggi)

Assegnista Post Doc

Laboratorio di Biologia Applicata, Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale. Via Bovio 6, 28100, Novara, Italia.

La dott.ssa Pinton ha focalizzato i suoi interessi scientifici allo studio della trasduzione del segnale recettore-mediata, all'analisi dell'espressione genica e proteica, alle modificazioni post-traduzionali delle proteine. Inoltre in ambito preclinico traslazionale ha indirizzato le sue ricerche alla valutazione dell'efficacia *in vitro* ed *in vivo* di molecole di interesse terapeutico.

(11/2015 – 12/2015)

Affidamento dei corsi "Laboratorio di Chimica Elementare" (40 ore) e "Esercitazioni Fondamenti neurobiologici e genetici dell'attività psichica" (12 ore) presso Università Cattolica del Sacro Cuore

(11/2010 – 02/2011)

Borsa di addestramento e perfezionamento alla ricerca

(11/2007 – 11/2010)

Dottorato di Ricerca

Laboratorio di Biologia Applicata, Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale.

Titolo tesi di dottorato: Estrogen receptor beta exerts tumor repressive functions in human malignant Pleural mesothelioma. Tutor: Prof.ssa Laura Moro.

(02/2009 – 05/2009)

Visiting PhD student presso il Lab. di Medicina Molecolare (Supervisor: Prof. B.J. Harvey) del Royal College of Surgeons (RCSI) Dublino, Irlanda.

ISTRUZIONE E FORMAZIONE

- (11/2007-11/2010) PhD in Biotecnologie Farmaceutiche e Alimentari
Università degli studi del Piemonte Orientale
Tesi di Dottorato: Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma.
- (11/2004-10/2006) Laurea magistrale (II livello) in Biotecnologie mediche e farmaceutiche
Università degli studi del Piemonte Orientale.
- (09/2001-11/2004) Laurea triennale (I livello) in Biotecnologie
Università degli studi del Piemonte Orientale.

1) A.G. Manente*, **G. Pinton***, S. Zonca, D. Tavian, T. Habib, Puthen V. Jithesh, D. Fennell, S. Nilsson and L. Moro. KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma. 2016 Epigenomics, in press.

* The authors contribute equally to the work.

2) **Pinton G**, Zonca S, Manente AG, Cavaletto M, Borroni E, Daga A, Jithesh PV, Fennell D, Nilsson S, Moro L. SIRT1 at the crossroads of AKT1 and ER β in malignant pleural mesothelioma cells. *Oncotarget*. 2016 7(12):14366-79.

3) Manente AG*, **Pinton G***, Zonca S, Cilli M, Rinaldi M, Daga A, Nilsson S, Moro L. Intracellular lactate-mediated induction of estrogen receptor beta (ER β) in biphasic malignant pleural mesothelioma cells. *Oncotarget*. 2015; 6(28):25121-34.

* The authors contribute equally to the work.

4) **Pinton G**, Manente AG, Daga A, Cilli M, Rinaldi M, Nilsson S, Moro L. Agonist activation of estrogen receptor beta (ER β) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity. *Mol Cancer*. 2014; 13:227

5) Manente AG, Valenti D, **Pinton G**, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L. Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. *Oncogenesis*. 2013 Sep 23;2:e72.

6) **Pinton G**, Manente AG, Tavian D, Moro L, Mutti L. Therapies currently in Phase II trials for malignant pleural mesothelioma. *Expert Opin Investig Drugs*. 2013; 22(10):1255-63.

7) **Pinton G**, Manente AG, Murer B, De Marino E, Mutti L, Moro L. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. *J Cell Mol Med* 2013; 17(2):233-41

8) **Pinton G**, Manente AG, Moro L, Mutti L. Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma. *Expert Opin Med Diagn* 2012; 6(3): 171-3

9) **Pinton G**, Manente AG, Angeli G, Mutti L, Moro L. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. *Plos One* 2012; 7(5):e36856

10) Manente AG, **Pinton G**, Tavian D, Lopez-Rodas G, Brunelli E, Moro L. Coordinated sumoylation and ubiquitination modulate EGF induced EGR1 expression and stability. *Plos One* 2011; 5(11):e14110

11) **Giulia Pinton**, Warren Thomas, Paolo Bellini, Arcangela Gabriella Manente, Roberto E Favoni, Brian J. Harvey, Luciano Mutti and Laura Moro. Estrogen receptor exerts tumor repressive functions in human malignant Pleural mesothelioma Via EGFR inactivation and affects response to Gefitinib. *Plos One* 2010; 5; (11): e14110

12) **Pinton G**, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. *Cancer Res*. 2009; 69(11):4598-604

13) Brunelli E, **Pinton G**, Bellini P, Minassi A, Appendino G, Moro L. Flavonoid-induced autophagy in hormone sensitive breast cancer cells. *Fitoterapia* 2009; 80(6):327-32

14) Brunelli E, **Pinton G**, Chianale F, Graziani A, Appendino G, Moro L. 8-Prenylnaringenin inhibits epidermal growth factor-induced MCF-7 breast cancer cell proliferation by targeting phosphatidylinositol-3-OH kinase activity. *J Steroid Biochem* 2009; 113: 163-70

Patent - Co-Inventor in the Patent Application N° WO/2015/082643 - International Application PCT/EP2014/076634 Publication date 11.06.2015. Estrogen receptor beta agonists for use in treating mesothelioma.

Patent - Co-Inventor in the Patent Application N°WO2016050945-International Application CT/EP2015/072763 Publication date 07.04.2016. Pharmaceutical combinations comprising estrogen receptor beta agonists with platinum drugs or paclitaxel for treating ovarian cancer.

Congressi (2010-2015)

Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Oral Presentation 2010 PePCon Beijing

Giulia Pinton, Warren Thomas, Paolo Bellini, Arcangela Gabriella Manente, Roberto E. Favoni, Brian J. Harvey, Luciano Mutti and Laura Moro. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Oral Presentation 2010 **ABCD Firenze**

Giulia Pinton, Warren Thomas, Paolo Bellini, Arcangela Gabriella Manente, Roberto E. Favoni, Brian J. Harvey, Luciano Mutti and Laura Moro. Estrogen receptor exerts tumor repressive functions in human malignant Pleural mesothelioma Via EGFR inactivation and affects response to Gefitinib. **IMIG (International Conference of the International Mesothelioma Interest Group) 2010 Kyoto**

Giulia Pinton, Warren Thomas, Paolo Bellini, Arcangela Gabriella Manente, Roberto E. Favoni, Brian J. Harvey, Luciano Mutti and Laura Moro. Estrogen receptor exerts tumor repressive functions in Human Malignant Pleural Mesothelioma. Presentazione orale. 2010 **Congresso AIBG Trento**

L. Moro, **G. Pinton**, W. Thomas, BJ Harvey, L. Mutti. Effect of estrogen receptor-beta on tumor-repressive functions in human malignant pleural mesothelioma. 2010 **ASCO-NCIEORTC Annual Meeting on Molecular Markers in Cancer**, Miami, USA.

Arcangela Gabriella Manente, Daniela Valenti, **Giulia Pinton**, Leonardo Rossi, Luciano Mutti, Dean Fennell, Anna Rosa Vacca and Laura Moro. Estrogen receptor-beta modulates mitochondrial functions in human malignant pleural mesothelioma cells. 2011 **Rapid responses to Steroid Hormones 7° International Meeting**, Creta, GR.

Arcangela Gabriella Manente, Daniela Valenti, **Giulia Pinton**, Leonardo Rossi, Luciano Mutti, Dean Fennell, Anna Rosa Vacca and Laura Moro. Estrogen receptor-beta modulates mitochondrial functions in human malignant pleural mesothelioma cells. 2011 **ABCD**, Ravenna, IT.

Giulia Pinton, Arcangela Gabriella Manente, Bruno Murer, Luciano Mutti and Laura Moro. Parp-1 inhibition as a novel therapeutical approach for malignant pleural mesothelioma. 2011 **XIII Convegno AIBG**, Padova, IT.

Giulia Pinton, Arcangela Gabriella Manente, Bruno Murer, Luciano Mutti and Laura Moro. Parp-1 inhibition as a novel therapeutical approach for malignant pleural mesothelioma. 2011 **XXIV Italian Meeting on ADP-ribosylation reactions**, Torre del Greco, IT, P2.

Arcangela Gabriella Manente, Daniela Valenti, **Giulia Pinton**, Leonardo Rossi, Luciano Mutti, Dean Fennell, Anna Rosa Vacca and Laura Moro. Estrogen receptor-beta modulates mitochondrial functions in human malignant pleural mesothelioma cells. 2012 **ABCD Meeting: "Mechanisms of Signal Transduction"**, Firenze, IT. **Oral presentation**

Pinton G, Manente AG, Daga A, Mutti L, Moro L, Nilsson S. Targeting estrogen receptor β for treatment of pleural malignant mesothelioma. 2012 **IMIG, Boston**.

Manente AG, Valenti D, **Pinton G**, Jithesh VP, Fennell D, Daga A, Rossi L, Gray S, O'Byrne K, Vacca AR, Nilsson S, Mutti L, Moro L. Estrogen receptor β activation impairs mitochondrial oxidative energy metabolism and affects malignant mesothelioma cell proliferation in vitro and in vivo. 2012 **IMIG, Boston**.

Pinton G, Manente AG, Borroni E, Mutti L, Moro L. Expression and post-translational modifications of AKT isoforms in Malignant pleural Mesothelioma cells. 2012 **IMIG, Boston**.

Pinton G, Manente AG, Borroni E, Mutti L, Moro L. Expression and post-translational modifications of AKT isoforms in Malignant pleural Mesothelioma cells. **2012 XIV Convegno AIBG, Assisi, IT**.

Manente AG, Valenti D, **Pinton G**, Jithesh VP, Fennell D, Daga A, Rossi L, Gray S, O'Byrne K, Vacca AR, Nilsson S, Mutti L, Moro L. Estrogen receptor β activation impairs mitochondrial oxidative energy metabolism and affects malignant mesothelioma cell proliferation in vitro and in vivo. 2013 **Keystone Symposia, PI3 kinase, Keystone, Colorado**.

Pinton G, Manente AG, Borroni E, Mutti L, Moro L. Expression and post-translational modifications of AKT isoforms in Malignant pleural Mesothelioma cells. **2013 Keystone Symposia, PI3 kinase, Keystone, Colorado**.

G. Pinton, A.G. Manente, E. Borroni, B. Murer, E. De Marino, L. Mutti, and L. Moro. PARP1 inhibition affects Pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. **2013 XXV Italian Meeting on ADP-ribosylation reactions, Pavia, IT**.

Giulia Pinton, Isacco Debernardi, Arcangela G. Manente, Sara Zonca, Maria Felicia Soluri, Szilvia Bakó, Daniele Sblattero and Laura Moro. TISSUE TRANSGLUTAMINASE 2 (TG2) AS A POTENTIAL NEW TARGET IN MALIGNANT PLEURAL MESOTHELIOMA. **IMIG (International Conference of the International Mesothelioma Interest Group) 2014 Cape Town, South Africa**.

Manente AG, **Pinton G**, Zonca S and Moro L. Targeting cancer metabolism for effective malignant pleural mesothelioma therapies. **Keystone Symposia Hypoxia: From Basic Mechanisms to Therapeutics (E3), Dublin, Ireland**.

Pinton G, Manente AG, Zonca S, Moro L. Expression and post-translational modifications of AKT isoforms in malignant pleural mesothelioma cells. **ABCD Congress, Bologna, Italy, 17-19 September**.

Redatto ai sensi degli artt. 46 e 47 del D.P.R. 28.12.2000, n. 445 (dichiarazioni sostitutive di certificazioni e dell'atto di notorietà).